What Eric J. Daniels’ appointment means for Plus Therapeutics and its CNS oncology pipeline
Plus Therapeutics has named Eric J. Daniels as Chief Development Officer. Read what this means for REYOBIQ, CNS oncology execution, and pipeline risk.
Whitehawk Therapeutics sharpens HWK-016 case as MUC16 emerges as a stronger ADC target in gynecologic cancers
Whitehawk Therapeutics says new MUC16 data support HWK-016 in gynecologic cancers. Read what this could change for ADC development.
What the NEOK002 IND milestone changes for Biocytogen, NEOK Bio, and ADC competition
NEOK002 has cleared the FDA IND stage. Read why this bispecific ADC matters for solid tumors, clinical strategy, and the next phase of ADC competition.
Triana Biomedicines tests degradation-first approach in ALK positive lung cancer with TRI-611
Triana Biomedicines launches TRI-611 trial in ALK lung cancer. Can molecular glue degraders overcome resistance? Read the full analysis.
What TAG1’s Lead-212 supply deal with Dana-Farber reveals about the future of radiopharmaceutical oncology
TAG1 and Dana-Farber partner to expand Lead-212 access for targeted alpha therapies. Discover what this means for radiopharmaceutical oncology innovation.
What the Senhwa Biosciences and CellType collaboration reveals about AI’s role in oncology pipelines
Senhwa Biosciences and CellType partner to advance silmitasertib with AI. Discover how the collaboration could reshape immunotherapy research.
Is Propanc Biopharma’s PRP proenzyme platform a credible challenger in the pancreatic oncology market?
Can Propanc Biopharma’s PRP therapy disrupt pancreatic cancer treatment? Explore the science, risks, and market implications of this emerging oncology approach.
Bristol Myers Squibb pushes CELMoD frontier as FDA accepts iberdomide NDA in relapsed multiple myeloma
FDA accepts Bristol Myers Squibb’s iberdomide NDA for relapsed multiple myeloma. Find out what this CELMoD filing could change next.
Why Deciphera Pharmaceuticals’ tirabrutinib NDA matters for the future of CNS lymphoma therapy
FDA accepts tirabrutinib NDA for relapsed or refractory PCNSL. Find out what this means for CNS lymphoma treatment and regulatory strategy.
Can Innovent’s IBI354 replace chemotherapy in first-line HER2-positive metastatic breast cancer
Innovent Biologics advances IBI354 into phase 3 first-line HER2-positive breast cancer. Find out what this means for ADC competition and clinical practice.